Autistic disorder - Pipeline Insight, 2023

DelveInsight's , "Autistic disorder - Pipeline Insight, 2023," report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Autistic disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Autistic disorder Understanding

Autistic disorder: Overview

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by deficits in social communication and the presence of restricted interests and repetitive behaviors. There is no clear-cut pathology of ASD however different populations have been suggested for different subtypes of ASD. The symptoms of ASD are usually identified by two years of age (specifically for CDD one-third of children experience regression of skills at the same time). Children with childhood disintegrative disorder generally have the worst outcome among individuals with ASD. Their cognitive and communication skills are affected. Most children with childhood disintegrative disorder experience a distinct prodrome characterized by bouts of anxiety and terror with no consistent medical, environmental, or psychosocial triggers. Children diagnosed with childhood disintegrative disorder rarely reveal an underlying neurological or medical cause. Complete medical and neurological examinations are done, and tests to exclude reversible causes of the condition. Treatment of childhood disintegrative disorder requires behavior therapy, environmental therapy, and medications. Medications are used to treat the symptoms as they develop during the disease as there is no drug available to cure this disease directly.

"Autistic disorder - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Autistic disorder pipeline landscape is provided which includes the disease overview and Autistic disorder treatment guidelines. The assessment part of the report embraces, in depth Autistic disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autistic disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

The companies and academics are working to assess challenges and seek opportunities that could influence Autistic disorder R&D. The therapies under development are focused on novel approaches to treat/improve Autistic disorder.

Autistic disorder Emerging Drugs Chapters

This segment of the Autistic disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Autistic disorder Emerging Drugs

CM-AT: Curemark

CM-AT is designed to enhance protein digestion thereby potentially restoring the pool of essential amino acids. Essential amino acids play a critical role in the expression of several genes important to neurological function and serve as precursors to key neurotransmitters such as serotonin and dopamine. CM-AT, has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA). FDA has also granted Curemark a rolling review of its New Drug Application for CM-AT.

L1-79: Yamo pharmaceuticals

L1-79 is an investigational drug currently in clinical development by Yamo Pharmaceuticals for the treatment of the core symptoms of ASD. L1-79 was granted Fast Track Designation by the Food and Drug Administration in May of 2018. It acts as a tyrosine hydroxylase inhibitor and is expected to modulate the catecholaminergic pathways implicated in ASD. L1-79 reported positive results from Phase II study in November 2021. Clinical studies are planned to further investigate the potential of L1-79 to improve the core symptoms of ASD.

Further product details are provided in the report……..

Autistic disorder: Therapeutic Assessment

This segment of the report provides insights about the different Autistic disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Autistic disorder

There are approx. 25+ key companies which are developing the therapies for Autistic disorder. The companies which have their Autistic disorder drug candidates in the most advanced stage, i.e. Preregistration include, Curemark

Phases

DelveInsight's report covers around 28+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Autistic disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as:

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Autistic disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Autistic disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Autistic disorder drugs.

Autistic disorder Report Insights

• Autistic disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Autistic disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Autistic disorder drugs?
• How many Autistic disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Autistic disorder?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Autistic disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Autistic disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Scioto Biosciences
• ACADIA Pharmaceuticals Inc.
• Yamo Pharmaceuticals LLC
• Stalicla SA
• MapLight Therapeutics
• Jazz Pharmaceuticals
• Neurotech International
• Axial Therapeutics, Inc.
• Hoffmann-La Roche
• Impel Pharmaceuticals
• PaxMedica
• SciSparc Ltd.
• BrainStorm Cell Therapeutics
• Enterin
• Monument Therapeutics
• IAMA Therapeutics
• Confluence Pharmaceuticals
• 4D Pharma PLC
• Key Products
• SB 121
• Pimavanserin
• FEN164
• L1-79
• ML-004
• GWP42003-P
• STP1
• NTI164
• AB-2004
• RO7017773
• INP105
• PAX-101
• SCI-210
• Autologous MSC-NTF
• ENT-01
• MT 1988
• IAMA-6
• IAMA 097
• MRx0006